Drug Discovery and Development: industry academic regulatory axis Flashcards
new drug development is
complex and involves;
academic institutions
pharmaceutical industry
gov. agencies
primary and clinical research funded by
National Institutes of Health
Food and Drug Administration FDA provides
regulatory review and oversees drug development process
investigational new drug (IND) application
used by FDA to regulate clinical testing in people
new drug application submitted by drug company
summarizes all data to determine risk/benefit analysis of new drug is sent to FDA for review and approval after testing.
investigators in clinical trials need
to understand regulatory development process and the national institutes of health funding process
department of health and human services from Food and Drug administration
has different agencies to approve either drugs, devices, evaluation of research, and biological evaluation
if product looks promising what happens?
preclinical development history and clinical development plan compiled in an investigational new drug application (IND) sumbmitted for FDA review and permission for human testing
an active IND permits?
clinical testing on humans
INDs are ?
dynamic documents residing with sponsor (company or individual) and updated annually for adverse events within clinical trial
IND include info in 3 areas:
1) animal testing for safety in humans
2) manufacturing information to ensure sponsor can produce and supply drug
3) clinical protocol to ensure safety of subjects from unnecessary risks and investigator information to ensure they are qualified to conduct clinical trial
letter code S or P assigned to each application by the FDA. Whats S and P?
S= standard review of a drug thats similar to those currently available (10 months) P= priority review is a quicker review for drug with significant advance over existing therapy (6 months)
NDA (new drug application)
submitted to FDA after phase III clinical trial in order to get approval and put out on market
when is IND sumbitted to FDA?
After pre- clinical phase to request for human testing in phase I
phase I key characteristics
first testing in humans
safe drug dose for phase II
few patients
phase II key characteristics
well defined eligibility criteria with placebo or active control and historical control
weeks- months study
establishes effectiveness by tumor shrinkage but does not garuntee survival in phase 3
large number of subjects (100-300)
phase III key characteristics
large study with hundreds-thousands of patients
confirm safety and efficacy
time: month-years
efficacy power greater than 80%, type 1 error rate alpha= 0.5 and P<0.05
phase IV key characteristics
post marketing studies provide additional safety and efficacy data
must be conducted if FDA approves product on fast track (before all premarketing data are compiled)
evaluates adverse data